

DOCTORAL THESIS

Glutamate antagonism as a potential treatment of Parkinson's Disease: a study in a rat model

Leung, Cheuk Hung

Date of Award:
2007

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

Glutamate Antagonism as a Potential Treatment of
Parkinson's Disease: A Study in a Rat Model

LEUNG Cheuk Hung

A thesis submitted in partial fulfillment of the requirements
for the degree of
Doctor of Philosophy

Principle Supervisor: Prof. YUNG Kin Lam

Hong Kong Baptist University

November, 2007

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disease and the patients suffer serious motor disorder. Degeneration of dopaminergic neurons is the cause of PD. Glutamate excitotoxicity is known to contribute to the progressive dopaminergic denervation and it is one main cause of motor symptoms of PD. Attenuation of glutamate excitotoxicity may be a valuable mean in both treatment of motor symptoms and neuroprotection of dopaminergic neurons.

In the present study, two different strategies were employed to attenuate glutamate excitotoxicity by the reduction of glutamate receptor, NMDA receptor, overstimulation and the removal of synaptically released glutamate by the upregulation of glutamate transporter. First, a single dose of a small interfering RNA (siRNA) that targets N-methyl-D-aspartate receptor one (NR1) (siRNA-NR1) was employed to reduce the protein expression of functional NMDA receptor in the striatum. After administration of the siRNA-NR1 into normal rats, the NR1 protein was significantly down-regulated in both immunofluorescence experiment and Western blot analysis. After the application of the siRNA-NR1 to the 6-hydroxydopamine- (6-OHDA)-lesioned rat, an animal model of PD, the grip strength and the number of contralateral rotation, which represented motor deficits, were found to be significantly reduced. The siRNA-NR1 was also found to decline the reduction of tyrosine-hydroxylase (TH)-positive cell ratio (lesion vs nonlesion) in SN of the 6-OHDA-lesioned rats.

Secondly, the effects of a neuroprotective antibiotic, ceftriaxone, was examined. Seven-day treatment of ceftriaxone was applied to the rats before the 6-OHDA lesion and five post-lesion time points were selected (day 2, 4, 6, 8 and 10) for analyses. By behavioral tests, ceftriaxone treatments were found to decrease both the grip strength and numbers of contralateral rotations in the 6-OHDA-lesioned rats. In addition, the reduction of tyrosine-hydroxylase (TH)-positive cell ratio (lesion vs nonlesion) in SN of the 6-OHDA-lesioned rats with ceftriaxone treatment was found to be decreased. Application of ceftriaxone enhanced the immunoreactivity and protein expression of GLT1. GLT1 is a major glial glutamate transporter and is responsible for re-cycling of synaptic glutamate. These results indicate that the up-regulation of GLT1 protein by the application of ceftriaxone inert neuroprotection of dopaminergic neurons.

In addition, co-administration of ceftriaxone and siRNA-NR1 was also applied in the 6-OHDA-lesioned rats. Significant reductions in both grip strength and the number of rotation were found in the co-treated animal groups when compared to the saline-treated animals. The degree of neuroprotection was similar between co-treatment and ceftriaxone treatment groups.

In conclusion, the present results as a whole have provided that glutamate antagonism

is beneficial to both amelioration of motor symptoms and neuroprotection of dopaminergic neurons. The present data can provide a basis for future development of non-dopaminergic therapies in treatment of PD.

Table of Contents

Declaration	i
Abstract	ii
Acknowledgements	iv
Table of Contents	v
List of Figures	x
List of Abbreviations	xiv
Chapter 1 Background and Literature Review	1
1.1 Parkinson's Disease	1
1.2 Basal Ganglia	2
1.2.1 Anatomical Structure of Basal Ganglia	2
1.2.2 Features of Each Regions Within the Basal Ganglia	3
1.2.2.1 Striatum (Str)	3
1.2.2.2 Golbus Pallidus (GP)	4
1.2.2.3 Subthalamic Nucleus (STN)	5
1.2.2.4 Substantia Nigra (SN)	6
1.2.3 Functions of the Basal Ganglia	7
1.2.4 Microcircuitry of the Basal Ganglia	7
1.3 Etiology of PD	9
1.4 Glutamate	10
1.5 Glutamate Receptors	11
1.5.1 Iontropic Glutamate Receptors	12
1.5.2 The Mechanisms of Iontropic Glutamate Receptors	13
1.6 Glutamate Transporters	14
1.7 Glutamate Excitotoxicity	15

1.8 Therapeutical Trend	16
1.9 Animal Model of PD	17
1.10 Objectives of the Thesis	19
Chapter 2 Materials and Methods	23
2.1 Animals	23
2.2 Six Hydroxydopamine Lesion	23
2.2.1 MFB Lesion	24
2.2.2 Striatal Lesion	24
2.3 Apomorphine-induced Rotation Test	25
2.4 Grasping Test	25
2.5 siRNA-NR1 Application	26
2.6 Ceftriaxone Pretreatment	26
2.7 Tissue Preparation	26
2.8 Immunocytochemical Staining	27
2.8.1 Single Immunoreactivity for Immunoperoxidase	27
2.8.2.1 Immunofluorescence Staining	28
2.8.2.2 Processing for Laser Scan Confocal Microscopy	29
2.9 Western Blotting	29
2.10 Semi-quantitative Analysis	31
Chapter 3 Effects of Administration of siRNA-NR1 in Six-hydroxydopamine-lesioned Rat	32
3.1 Introduction	32
3.1.1. Striatum as the Target Region for Treatment of PD	32
3.1.2 NMDA Receptor as the target for Treatment	33
3.1.3 Application of siRNA	35

3.1.4 Mechanism of siRNA in the Down-regulation of Protein Expression	36
3.2 Objectives	37
3.3 Materials and Methods	38
3.4 Results	39
3.4.1.1 The Effect of siRNA-NR1 on Rotation Tests	39
3.4.1.2 Effects of siRNA-NR1 on Motor Strength	40
3.4.2 Change in TH Immunoreactivity After siRNA-NR1 Administration	40
3.4.3 Change in NR1 Immunoreactivity After siRNA-NR1 Administration in Normal Animals	41
3.4.3.1 Change in NR1 Immunoreactivity After siRNA-NR1 Administration in 6-OHDA-lesioned Rats After siRNA-NR1 Treatment	41
3.4.4 NR1 Protein Expression in Normal Rats After siRNA-NR1 Treatments	42
3.4.5 NR1 Protein Expression in Lesion Animals After siRNA-NR1 Treatments	42
3.5 Discussion	43
3.5.1 siRNA Affects Glutamatergic Transmission	43
3.5.2 siRNA Affects NMDA Receptor Functions	44
3.5.3 siRNA Brings Neuroprotection of Dopaminergic Neurons	47
3.5.4 Glutamate and Dopamine Interactions	47
3.5.5 Unleash the Power of siRNA Therapy	48
Chapter 4 Ameliorations of Motor Symptoms and Neuroprotective Effects of Ceftriaxone in the Six-hydroxydopamine-lesioned Rat	69
4.1 Introduction	69
4.2 Objectives	72
4.3 Materials and Methods	73

4.4 Results	74
4.4.1 Effects of Ceftriaxone Pretreatment on Muscular Rigidity and Contralateral Rotation in 6-OHDA-lesioned Rats	74
4.4.2 Tyrosine Hydroxylase Labeling in the Str and SN	75
4.4.3 Effects of Ceftriaxone Treatments on GLT1 Immunoreactivity	75
4.4.4 Changes in the Protein Expression of TH and GLT1 After Ceftriaxone Treatment	76
4.5 Discussion	77
4.5.1 GLT1 Levels and Neuroprotection	77
4.5.2 Up-regulation of GLT1	78
4.5.3 GLT1 Protein Level and Activity	80
4.5.4 Possible Mechanisms of GLT1 Up-regulation	80
4.5.5 Ceftriaxone May Mediate Other Forms of Neuroprotective Effects	82
4.5.6 Applicability of Ceftriaxone	82
Chapter 5 Co-administration of siRNA-NR1 and Ceftriaxone in the Six-hydroxydopamine-lesioned Rat: Synergism in Treatment?	102
5.1 Introduction	102
5.2 Objectives	104
5.3 Materials and Methods	105
5.4 Results	106
5.4.1 Co-administrations of siRNA-NR1 and Ceftriaxone on Motor Behaviors	106
5.4.2 Neuroprotective Effect on the TH-positive Neurons in the SN	106
5.4.3 Changes in NR1 and GLT1 Immunoreactivity After Co-administration	107

5.4.3.1 Down-regulation of NR1 After Administration of siRNA-NR1	107
5.4.3.2 Up-regulation of GLT1 After 7 days Administration of Ceftriaxone	107
5.5 Discussion	108
5.5.1 Co-administration of siRNA-NR1 and Ceftriaxone Offers Synergism in Amelioration of Motor Symptoms and Neuroprotection?	108
5.5.2 Interaction Between NMDA Receptors and GLT1 Protein Expression	109
5.5.3 NMDA Receptor Activation and Glutamate Transporters	111
Chapter 6 Summary and Conclusion	126
6.1 Introduction	126
6.2 Other Possible Targets for Glutamate Antagonism	126
6.3 The Present Results May Path Novel Drugs for Treatment of PD	127
6.4 Further Investigations	127
6.5 Conclusion	129
List of References	130
Appendix I	156
Appendix II	157
Appendix III	158
Curriculum Vitae	162